● Recruiting

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Condition: C3 Glomerulopathy · Immune-complex-membranoproliferative Glomerulonephritis · Sponsor: Novartis Pharmaceuticals

PhasePhase 3

Planned participants225

Who can joinAll sexes, 12 Years to 100 Years

Healthy volunteersNo

About this study

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111

Always discuss trial participation with your own doctor first.

Locations (53)

Childrens Hospital Colorado	Aurora, Colorado, United States	Recruiting
Georgia Nephrology Research Inst	Lawrenceville, Georgia, United States	Recruiting
University of Iowa Health Care	Iowa City, Iowa, United States	Recruiting
University of Minnesota	Minneapolis, Minnesota, United States	Recruiting
Col Uni Med Center New York Presby	New York, New York, United States	Recruiting
Novartis Investigative Site	CABA, Buenos Aires, Argentina	Recruiting
Novartis Investigative Site	Buenos Aires, Argentina	Recruiting
Novartis Investigative Site	Belo Horizonte, Minas Gerais, Brazil	Recruiting
Novartis Investigative Site	Recife, Pernambuco, Brazil	Recruiting
Novartis Investigative Site	Porto Alegre, Rio Grande do Sul, Brazil	Recruiting
Novartis Investigative Site	Botucatu, São Paulo, Brazil	Recruiting
Novartis Investigative Site	São Paulo, São Paulo, Brazil	Recruiting

+ 41 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03955445